GLP-1 Manufacturer Savings Cards in 2026: Eligibility and Limits
Novo Nordisk and Eli Lilly copay-card rules, monthly caps, and who actually qualifies.
Key takeaways
Manufacturer savings cards for Wegovy, Zepbound, Saxenda, Ozempic, and Mounjaro typically exclude patients with Medicare, Medicaid, TRICARE, or any other government insurance, which removes roughly one in three U.S. adults from eligibility.
The advertised $25 copay applies almost exclusively to commercially insured patients whose plan already covers the medication; patients without coverage face a separate, much higher monthly cap that still leaves hundreds out of pocket.
Wegovy and Zepbound both offer cash-pay direct programs (NovoCare and LillyDirect) with vial pricing that is often lower than running a savings card through an uncovered commercial plan, so the right path depends on coverage status.
Savings cards have annual maximum benefits, expire each calendar year, and require re-enrollment, which means a card that worked in January may stop reducing your price by November even with the same prescription.
Compounded GLP-1 medications are not FDA-approved finished products and are not eligible for any manufacturer savings card; only brand-name Wegovy, Zepbound, Saxenda, Ozempic, and Mounjaro qualify.
How Manufacturer Savings Cards Actually Work
Manufacturer savings cards are coupons issued by drug makers that reduce the patient's out-of-pocket cost at the pharmacy counter. They do not change the list price of the medication; they reimburse the pharmacy for a portion of your copay after your commercial insurance has processed the claim. That two-step structure is the single most important thing to understand before you apply.
Because savings cards sit on top of commercial insurance, they only work efficiently when your plan already covers the drug. If or is on your plan's formulary, the card can drop your monthly copay to as little as $25. If it is excluded from your formulary, the card switches to a different, much smaller benefit tier and you may pay several hundred dollars per month even with the card active.
Federal law also prohibits manufacturer savings cards from being used with any government-funded insurance program. This includes Medicare, Medicaid, Medicare Advantage, TRICARE, VA benefits, and the Federal Employees Health Benefits program. The exclusion is not optional and not negotiable at the pharmacy; it is built into the terms of use of every card discussed in this article.
The savings offer from Novo Nordisk has historically split patients into two tracks based on whether their commercial plan covers the drug. Patients with coverage may pay as little as $0 to $25 per 28-day supply, subject to a monthly maximum savings cap set by the manufacturer. Patients whose commercial plan excludes Wegovy from the formulary receive a much smaller discount and typically pay a few hundred dollars per month.
Eligibility requires a valid Wegovy prescription, U.S. residency, and commercial insurance. Patients enrolled in Medicare, Medicaid, TRICARE, the VA system, or any other state or federal health program are excluded. The card also has an annual maximum benefit, meaning that even an eligible patient may exhaust the savings before the calendar year ends and revert to their standard commercial copay.
In 2024 and 2025, Novo Nordisk also launched NovoCare Pharmacy, a direct-to-patient cash channel for self-pay Wegovy customers. NovoCare pricing is separate from the savings card program and is generally aimed at patients without commercial coverage. Whether the savings card or NovoCare is cheaper depends entirely on your specific insurance status, so it is worth checking both before filling a prescription.
Zepbound Savings Card: Pen vs Vial Pricing
Eli Lilly's savings card follows the same two-track structure as Wegovy. Commercially insured patients whose plan covers Zepbound can pay as little as $25 per month, subject to a monthly maximum savings cap. Commercially insured patients whose plan excludes Zepbound pay a substantially higher monthly amount, usually several hundred dollars, even with the card active.
Zepbound is unique because Lilly also sells the medication directly to patients through LillyDirect as single-dose vials, separate from the prefilled autoinjector pens covered by the savings card. The vial program is designed for self-pay patients and has its own list price, which Lilly has periodically discounted. Vials require the patient to draw up and inject the dose with a separate syringe, and your prescriber will determine whether that delivery method is appropriate for you.
Because pen and vial pricing are tracked separately, patients sometimes find that the LillyDirect vial is cheaper than running a savings card through an uncovered commercial plan. In other cases, the savings card on covered insurance wins. The decision is not obvious from the marketing pages, so checking both your insurance formulary status and current vial pricing is the practical way to compare.
Zepbound was FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Eligibility for the savings card does not require the patient to have hit any specific BMI threshold beyond the prescriber's medical judgment, but the card does require the prescription to be for an on-label indication.
Saxenda Savings Card: The Older Daily-Injection Option
(liraglutide) is the older daily-injection GLP-1 from Novo Nordisk, FDA-approved for chronic weight management in 2014. Its savings card follows the same broad rules as the Wegovy card: commercial insurance required, government insurance excluded, and a tiered benefit structure depending on whether the drug is covered by the patient's plan.
Because Saxenda is dosed daily rather than weekly, the SCALE trial program showed an average weight loss of roughly 8 percent of body weight at one year, lower than what newer agents like Wegovy and Zepbound achieved in their respective STEP and SURMOUNT trials. Many commercial plans have shifted their preferred GLP-1 toward weekly options, so Saxenda's formulary status is increasingly inconsistent across employer plans.
Patients considering Saxenda often do so because their plan covers it when it does not cover Wegovy or Zepbound, or because their prescriber prefers a shorter-acting molecule for clinical reasons. Your prescriber will determine which GLP-1 fits your specific situation; this article is not a substitute for that conversation.
Ozempic and Mounjaro: Diabetes-Only Savings Cards
(semaglutide) and (tirzepatide) are FDA-approved for type 2 diabetes, not for weight management. Their manufacturer savings cards reflect that indication. Both cards require the patient to have a type 2 diabetes diagnosis and a prescription written for that condition. Off-label use for weight loss alone does not qualify for the savings card, even when the medication itself is the same molecule as the weight-management version.
For eligible patients with commercial insurance, the Ozempic savings offer has historically capped out-of-pocket costs at $25 per month for up to 24 months, with an annual maximum benefit. The Mounjaro savings card follows a similar structure with a $25 monthly target on covered commercial plans and a different, higher cap on plans that do not cover the drug.
The government-insurance exclusion is again strict. Medicare Part D patients with type 2 diabetes can typically get Ozempic and Mounjaro covered through their plan, but they cannot use the manufacturer savings card to lower their copay. For Medicare patients hitting a high Part D copay, the Inflation Reduction Act's $2,000 annual out-of-pocket cap, which took full effect in 2025, is generally a more relevant cost lever than any manufacturer coupon.
Side-by-Side Comparison of the Five Major Cards
Comparing the five major GLP-1 savings cards on a single axis is misleading because each one has different fine print. The table below summarizes the practical differences that matter most when a patient is choosing between cards, but the actual dollar amount you will pay depends on your insurance, your pharmacy, and the calendar year.
A few patterns hold across all five cards. First, the headline $25 price always assumes commercial insurance that already covers the drug. Second, the much larger monthly cap that applies when the drug is not covered still leaves the patient paying hundreds of dollars. Third, all five cards exclude government insurance. Fourth, none of the cards apply to compounded versions of the medications.
Wegovy (semaglutide, Novo Nordisk): commercial insurance required, government insurance excluded, on-label weight management prescription required, annual maximum benefit applies, NovoCare cash channel available separately.
Zepbound (tirzepatide, Eli Lilly): commercial insurance required, government insurance excluded, on-label weight management prescription required, LillyDirect vial channel available separately at different list price.
Saxenda (liraglutide, Novo Nordisk): commercial insurance required, government insurance excluded, daily injection rather than weekly, increasingly inconsistent formulary coverage across commercial plans.
Ozempic (semaglutide, Novo Nordisk): commercial insurance required, government insurance excluded, type 2 diabetes diagnosis required, off-label weight-loss prescriptions do not qualify.
Mounjaro (tirzepatide, Eli Lilly): commercial insurance required, government insurance excluded, type 2 diabetes diagnosis required, off-label weight-loss prescriptions do not qualify.
Who Actually Qualifies in 2026
The shorthand version is that a savings card is most valuable to a working-age adult with employer-sponsored commercial insurance whose plan already covers the specific GLP-1 they have been prescribed. For that patient, the $25 monthly copay is realistic, at least until the annual maximum benefit is exhausted.
The card is least useful, despite the marketing, for three large groups. Medicare beneficiaries are excluded by federal law regardless of income. Medicaid recipients are excluded for the same reason. Commercially insured patients whose plan excludes the drug from its formulary receive only a modest discount, often paying $500 or more per month even with the card active.
The Kaiser Family Foundation has tracked GLP-1 coverage gaps closely, noting that a substantial share of employer plans either exclude weight-management drugs entirely or impose prior authorization, BMI thresholds, and step-therapy requirements that delay access. The savings card does nothing to overcome those plan-design barriers; it only reduces the copay once the prescription is approved and processed.
Cash-Pay Alternatives When the Card Does Not Help
Patients who do not qualify for a savings card have a small set of legitimate alternatives. Novo Nordisk's NovoCare Pharmacy and Eli Lilly's LillyDirect both sell their respective branded products directly to self-pay patients, often at prices below what an uncovered commercial plan would charge with a card. These programs are not free, but they remove the insurance-formulary trap.
Compounded semaglutide and tirzepatide became widely available during the FDA-declared shortages of the brand-name products. As of the FDA's 2024 and 2025 enforcement actions, the shortages were declared resolved, and the regulatory pathway for 503A and 503B compounders to produce these molecules narrowed substantially. Compounded versions are not FDA-approved as finished products, are not eligible for any manufacturer savings card, and may carry quality and dosing risks your prescriber should evaluate.
Patient assistance programs from both manufacturers exist for very low-income, uninsured patients who meet specific income thresholds. These are separate from the commercial savings card and have their own application process. GLP1Zoom doesn't prescribe or sell medication — we compare and redirect to licensed providers, and we encourage patients exploring these programs to work with their prescriber and the manufacturer's patient support line.
Practical Steps Before You Apply for a Card
Before you click apply on any manufacturer savings card landing page, a short pre-flight check will save time and disappointment. The goal is to confirm that the card will actually deliver the headline price for your specific situation rather than the much smaller fallback benefit.
Knowing your insurance type, your plan's formulary status for the specific GLP-1 your prescriber has chosen, and any prior authorization requirements will tell you most of what you need to know. If any of those three answers is unfavorable, the savings card alone will not solve the cost problem and you should ask your prescriber about alternative options.
Confirm whether your insurance is commercial or government-funded. Medicare, Medicaid, TRICARE, VA, and FEHB are all excluded from every GLP-1 savings card discussed here.
Call your insurance carrier or check the formulary online to see whether the specific GLP-1 your prescriber wrote for is covered, and whether prior authorization or step therapy is required.
Ask the prescriber's office to submit any required prior authorization before you try to fill the prescription, since the card cannot rescue a denied claim.
Review the savings card terms for the annual maximum benefit and note the expiration date, because most cards reset each calendar year and require re-enrollment.
Compare the savings card price against the manufacturer's cash-pay channel (NovoCare for Novo Nordisk products, LillyDirect for Zepbound) before committing to a fill location.
What This Article Is and Is Not
This article summarizes publicly available information about manufacturer savings card structures as of early 2026. It does not list every dollar amount, because manufacturers update those figures throughout the year and the only authoritative source is the manufacturer's own savings program page at the time of fill. Treat the numbers in this article as orientation, not as a quote.
Nothing here is medical advice. The choice between Wegovy, Zepbound, Saxenda, Ozempic, Mounjaro, or any other GLP-1 is a clinical decision that depends on your diagnosis, comorbidities, prior medication history, and treatment goals. Your prescriber will determine which medication and which dose is appropriate for you, and they are also the right person to help you weigh cost-coverage trade-offs against clinical fit.
Frequently asked questions
Can I use the Wegovy savings card if I have Medicare?
No. The Wegovy savings card, like every other manufacturer GLP-1 savings card, excludes patients enrolled in Medicare, Medicare Advantage, Medicare Part D, Medicaid, TRICARE, VA benefits, and the Federal Employees Health Benefits program. This exclusion is a federal anti-kickback requirement, not a Novo Nordisk policy choice, and it cannot be waived at the pharmacy counter. Medicare patients seeking GLP-1 coverage should focus on plan-design questions like Part D formulary status and the post-2025 $2,000 annual out-of-pocket cap instead.
Why is my Zepbound copay still hundreds of dollars even with the savings card?
The Zepbound savings card delivers its headline $25 monthly price only when your commercial insurance already covers the drug. If your plan excludes Zepbound from its formulary, the card switches to a much smaller discount tier intended to reduce a cash-pay price rather than a covered copay, and you typically end up paying several hundred dollars per month. Checking your plan's formulary before you fill is the only way to know in advance which tier you will land in, and a prior authorization or formulary exception request may move you onto the covered tier.
Do manufacturer savings cards apply to compounded semaglutide or tirzepatide?
No. Manufacturer savings cards apply only to the brand-name, FDA-approved finished products: Wegovy, Zepbound, Saxenda, Ozempic, and Mounjaro. Compounded semaglutide and tirzepatide are not FDA-approved as finished products and are dispensed by 503A or 503B compounding pharmacies under a separate regulatory pathway. Novo Nordisk and Eli Lilly do not subsidize compounded versions of their molecules, and any pharmacy that claims to apply a manufacturer card to a compounded product is misrepresenting the program's terms of use.
Is the LillyDirect Zepbound vial cheaper than using the savings card?
It depends on your insurance status. For patients with commercial insurance that covers Zepbound on its formulary, the savings card on the standard prefilled pens is usually the lowest out-of-pocket option. For patients without insurance coverage, or whose commercial plan excludes Zepbound, the LillyDirect single-dose vial program is often less expensive than running a savings card through an uncovered plan. The right comparison is your specific covered-pen copay against the current LillyDirect vial list price at the time you fill.
How often do the savings card terms change?
Manufacturers update savings card terms, monthly caps, annual maximum benefits, and program expiration dates at least annually, and sometimes mid-year. A card that delivered $25 monthly pricing in January may have a lower annual maximum or different fallback tier by November. The only authoritative source is the manufacturer's official savings program page at the moment you apply or re-enroll. Re-checking the terms each January and any time you change insurance is a reasonable habit for patients on long-term GLP-1 therapy.
Does the savings card cover all dose strengths of Wegovy or Zepbound?
Both Wegovy and Zepbound are titrated through several dose strengths during the first months of treatment, and the manufacturer savings cards generally apply to all FDA-approved on-label dose strengths rather than only the maintenance dose. The card applies per 28-day supply, regardless of which titration step you are on. However, your prescriber, not the savings card, decides which strength is appropriate at each stage, and skipping or accelerating titration to manage cost is not advisable without medical guidance.
Can a savings card be combined with an HSA or FSA?
In most cases, you can pay the post-card copay amount with HSA or FSA funds, since the remaining out-of-pocket cost is still a qualified medical expense. However, you cannot double-count the discount: the value the manufacturer covered through the savings card is not your expense and is not HSA or FSA eligible. Tax treatment can vary by plan and by state, so confirm with your benefits administrator if you are pairing a savings card with a tax-advantaged spending account for the first time.
We cite primary sources — FDA-approved prescribing information (DailyMed), ClinicalTrials.gov registry IDs, and peer-reviewed publications — over secondary commentary. Every medical claim is re-checked at least every 6 months. Spot something wrong? Tell us. See our full editorial policy.